| Summary of milestone payment |
|
Milestones
|
|
Payments
|
|
|
|
|
|
|
|
(1) when Company initiates a Phase I Clinical Trial of a licensed product
|
|
$
|
750,000
|
|
|
(2) when Company initiates a Phase II Clinical Trial of a licensed product
|
|
|
750,000
|
|
|
(3) when Company initiates a Phase III Clinical Trial of a licensed product
|
|
|
1,500,000
|
|
|
(4) Biological License Application filing with U.S. FDA
|
|
|
1,750,000
|
|
|
(5) First commercial sale
|
|
|
1,500,000
|
|
|
(6) after the first $10,000,000 in net sales
|
|
|
1,500,000
|
|
|
|
Milestones
|
|
Payments
|
|
| |
|
|
|
|
(1) when Company initiates a Phase I Clinical Trial of a licensed product
|
|
$
|
750,000
|
|
|
(2) when Company initiates a Phase II Clinical Trial of a licensed product
|
|
|
750,000
|
|
|
(3) when Company initiates a Phase III Clinical Trial of a licensed product
|
|
|
1,500,000
|
|
|
(4) Biological License Application filing with U.S. FDA
|
|
|
1,750,000
|
|
|
(5) First commercial sale
|
|
|
1,500,000
|
|
|
(6) after the first $10,000,000 in net
sales
|
|
|
1,500,000
|
|
|
| Summary of milestone payment |
|
Milestones
|
|
Payments
|
|
| |
|
|
|
(1) filing of an New Drug Application (“NDA”) or regulatory approval for each licensed product
|
|
$
|
750,000
|
|
(2) upon the receipt of regulatory approval from the U.S. FDA for each licensed product
|
|
|
1,750,000
|
|
|
|
Milestones
|
|
Payments
|
|
| |
|
|
|
|
1) filing of an New Drug Application (“NDA”) or regulatory approval
|
|
|
|
|
for each licensed product
|
|
$
|
750,000
|
|
|
(2) upon the receipt of regulatory approval from the U.S. FDA for each
|
|
|
|
|
|
licensed product
|
|
|
1,750,000
|
|
|